{
  "query": "what evidence is there for dexamethasone as a treatment for COVID-19?",
  "keqe_expansions": [
    "Dexamethasone has emerged as a potential treatment for COVID-19 based on evidence from the RECOVERY trial conducted in the United Kingdom. This study showed that dexamethasone, a corticosteroid medication, reduced mortality rates in COVID-19 patients requiring respiratory support, such as mechanical ventilation or oxygen therapy. The trial results indicated that dexamethasone was most effective in severe cases of COVID-19, where the body's immune response can lead to harmful inflammation. The anti-inflammatory properties of dexamethasone help to mitigate this immune response and improve outcomes for severely ill patients. This evidence suggests that dexamethasone can be a valuable treatment option in managing COVID-19, particularly in critically ill patients.",
    "Dexamethasone has emerged as a potential treatment for COVID-19 based on the findings of the RECOVERY trial, a large-scale clinical trial conducted in the United Kingdom. The study revealed that dexamethasone, a corticosteroid medication, reduced mortality rates among hospitalized COVID-19 patients who required respiratory support. Specifically, the treatment showed a significant decrease in deaths among patients on ventilators by one-third and by one-fifth among those receiving oxygen without mechanical ventilation. This evidence suggests that dexamethasone may be an effective therapeutic option for severe cases of COVID-19 by reducing inflammation and improving outcomes. Additional research and clinical trials are ongoing to further elucidate the efficacy and potential side effects of dexamethasone in treating COVID-19."
  ],
  "csqe_expansions": [
    "what evidence is there for dexamethasone as a treatment for COVID-19, The most common manifestation of SARS-CoV2 infection (Coronavirus disease 2019 - COVID-19) is viral pneumonia with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop Acute Respiratory Distress Syndrome (ARDS). Several clinical trials evaluated the role of corticosteroids in non-COVID-19 ARDS with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration... Background: Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death... We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone. Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties... We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.",
    "what evidence is there for dexamethasone as a treatment for COVID-19? OBJECTIVES: We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. METHODS: We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone or in addition METHODS We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone"
  ],
  "top_passages": [
    "Multiple Myeloma in the Time of COVID-19\tWe provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done in all patients before therapy. For standard-risk patients, we recommend the following: ixazomib, lenalidomide, and dexamethasone (IRd) (preferred), cyclophosphamide lenalidomide and dexamethasone (CRd), daratumumab lenalidomide and dexamethasone (DRd), lenalidomide, bortezomib, and dexamethasone (RVd), or cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For high-risk patients we recommend carfilzomib, lenalidomide,",
    "Multiple Myeloma in the Time of COVID-19\tWe provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done in all patients before therapy. For standard-risk patients, we recommend the following: ixazomib, lenalidomide, and dexamethasone (IRd) (preferred), cyclophosphamide lenalidomide and dexamethasone (CRd), daratumumab lenalidomide and dexamethasone (DRd), lenalidomide, bortezomib, and dexamethasone (RVd), or cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For high-risk patients we recommend carfilzomib, lenalidomide,",
    "COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial.\tOBJECTIVES: The infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) spreads worldwide and is considered a pandemic. The most common manifestation of SARS-CoV2 infection (Coronavirus disease 2019 - COVID-19) is viral pneumonia with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop Acute Respiratory Distress Syndrome (ARDS). Several clinical trials evaluated the role of corticosteroids in non-COVID-19 ARDS with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of",
    "Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials\tThe following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50\u20131.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80\u20135.84]). Arbidol showed no",
    "Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report\tBackground: Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death. Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. The primary outcome was 28-day mortality. Results: 2104 patients randomly allocated to receive dexamethasone",
    "Short-Term Dexamethasone in Sars-CoV-2 Patients\tBACKGROUND: Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties There is a hyperinflammatory response involved in the clinical course of patients with pneumonia due to SARS-CoV-2 To date, there has been no definite therapy for COVID-19 We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone METHODS: We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone or in addition",
    "Short-Term Dexamethasone in Sars-CoV-2 Patients.\tBACKGROUND Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties. There is a hyperinflammatory response involved in the clinical course of patients with pneumonia due to SARS-CoV-2. To date, there has been no definite therapy for COVID-19. We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone. METHODS We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone",
    "Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective\tCoronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared \u201cpandemic\u201d by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular",
    "CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial\tBACKGROUND: Cryptococcal meningitis (CM) is a severe AIDS-defining illness with 90-day case mortality as high as 70% in sub-Saharan Africa, despite treatment. It is the leading cause of death in HIV patients in Asia and Africa. No major advance has been made in the treatment of CM since the 1970s. The mainstays of induction therapy are amphotericin B and flucytosine, but these are often poorly available where the disease burden is highest. Adjunctive treatments, such as",
    "Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial\tOBJECTIVES: There is little information about Coronavirus Disease 2019 (COVID-19) management for critically ill patients. Most of these patients develop acute respiratory distress syndrome (ARDS) due to excessive inflammatory response and the ensuing cytokine storm. Anti-inflammatory drugs including corticosteroids can be used to effectively reduce the effect of this cytokine storm and lung damage. However, corticosteroids can have side effects, so simultaneous administration of immunoglobulin (IV-IG) and interferon-"
  ],
  "combined_expansion": "what evidence is there for dexamethasone as a treatment for COVID-19? what evidence is there for dexamethasone as a treatment for COVID-19? Dexamethasone has emerged as a potential treatment for COVID-19 based on evidence from the RECOVERY trial conducted in the United Kingdom. This study showed that dexamethasone, a corticosteroid medication, reduced mortality rates in COVID-19 patients requiring respiratory support, such as mechanical ventilation or oxygen therapy. The trial results indicated that dexamethasone was most effective in severe cases of COVID-19, where the body's immune response can lead to harmful inflammation. The anti-inflammatory properties of dexamethasone help to mitigate this immune response and improve outcomes for severely ill patients. This evidence suggests that dexamethasone can be a valuable treatment option in managing COVID-19, particularly in critically ill patients. Dexamethasone has emerged as a potential treatment for COVID-19 based on the findings of the RECOVERY trial, a large-scale clinical trial conducted in the United Kingdom. The study revealed that dexamethasone, a corticosteroid medication, reduced mortality rates among hospitalized COVID-19 patients who required respiratory support. Specifically, the treatment showed a significant decrease in deaths among patients on ventilators by one-third and by one-fifth among those receiving oxygen without mechanical ventilation. This evidence suggests that dexamethasone may be an effective therapeutic option for severe cases of COVID-19 by reducing inflammation and improving outcomes. Additional research and clinical trials are ongoing to further elucidate the efficacy and potential side effects of dexamethasone in treating COVID-19. what evidence is there for dexamethasone as a treatment for COVID-19, The most common manifestation of SARS-CoV2 infection (Coronavirus disease 2019 - COVID-19) is viral pneumonia with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop Acute Respiratory Distress Syndrome (ARDS). Several clinical trials evaluated the role of corticosteroids in non-COVID-19 ARDS with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration... Background: Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death... We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone. Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties... We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone. what evidence is there for dexamethasone as a treatment for COVID-19? OBJECTIVES: We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. METHODS: We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone or in addition METHODS We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone"
}